个人简介
陈承瑜，男，1986年生，澳门科技大学中药学博士，主要的研究方向是中药抗肿瘤活性成分的分离纯化，先后从蒲公英、三分丹、过山枫和全缘叶绿绒蒿四种药材中分离鉴定了105个化合物，其中新化合物37个，涉及生物碱、C21甾体、三萜等多种结构类型，发表SCI学术论文8篇，获得1个澳洲专利。
陈承瑜目前就职于盈科瑞横琴药物研究院，参与了中药注射剂再评价、中药雾化吸入制剂、中药抗新冠病毒药物等多个研发项目，积累了丰富的产业经验。
专利
1、Method of isolation phenanthroindolizidine alkaloids from Tylophora atrofolliculata with HIF-1 inhibitory activity, compositions comprising them and their use (专利号：2016100494)
科研项目 共7项
中药雾化吸入制剂“银黄吸入溶液”研发的关键技术研究
部分学术论文 共10篇
Aculeatusane A: A new diterpenoid from the whole plants of Celastrus aculeatus Merr （第一作者）,Phytochem Lett,2020
Three new C21 steroidal glycosides from Tylophora atrofolliculata（第一作者）,Phytochem Lett,2020
A phenanthroindolizidine glycoside with HIF-1 inhibitory activity from Tylophora atrofolliculata （第一作者）,Phytochem Lett,2017
Phenanthroindolizidine alkaloids from Tylophora atrofolliculata with hypoxia-inducible factor-1 inhibitory activity （第一作者）,RSC Adv,2016
G-Quadruplex DNA-binding quaternary alkaloids from Tylophora atrofolliculata （第一作者）,RSC Adv,2016
Antioxidant activity and components of a traditional chinese medicine formula consisting of Crataegus pinnatifida and Salvia miltiorrhiza （第一作者）,BMC Complem Altern M,2013
Comparative chemical and statistical analysis of cultivated and wild Radix Scutellariae（第一作者）,AM J Chinese Med,2011
LC-MS based sphingolipidomic study on A2780 human ovarian cancer cell line and its taxol resistant strain,Sci Rep,2016
Characterization of oxygenated metabolites of ginsenoside Rg1 in plasma and urine of rat,J Chromatogr B,2016
Method of isolation phenanthroindolizidine alkaloids from Tylophora atrofolliculata with HIF-1 inhibitory activity, compositions comprising them and their use,澳洲专利,2016
